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Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) in flame-dried or oven-dried 
glassware under argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed over a 
column of activated alumina).1 Commercially obtained reagents were used as received unless otherwise stated. 
NEt3 was distilled from calcium hydride immediately prior to use. Reactions requiring external heat were 
modulated to the specified temperatures using an IKAmag temperature controller. Reaction progress was 
monitored by thin-layer chromatography (TLC) or Agilent 1290 UHPLC-LCMS. TLC was performed using E. 
Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or p-anisaldehyde staining. SiliaFlash P60 Academic Silica gel (particle size 0.040-0.063 mm) 
was used for flash chromatography. 1H and 13C NMR spectra were recorded on a Varian Inova 500 spectrometer 
(500 MHz and 126 MHz, respectively) and are reported in terms of chemical shift relative to residual CHCl3 (δ 
7.26 and δ 77.16 ppm, respectively), D3CS(O)CHD2 (δ 2.50 and δ 39.52 ppm, respectively). Data for 1H NMR 
are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities 
are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, m = 
multiplet, br s = broad singlet, br d = broad doublet, app = apparent. Data for 13C NMR are reported in terms of 
chemical shifts (δ ppm). IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using thin 
films deposited on NaCl plates and reported in frequency of absorption (cm-1). Optical rotations were measured 
with a Jasco P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100 mm path-length cell and 
are reported as: [α]DT (concentration in g/100 mL, solvent). Analytical HPLC was performed with an Agilent 
1100 Series HPLC utilizing a Chiralpak (AD-H) column (4.6 mm x 25 cm) obtained from Daicel Chemical 
Industries, Ltd. Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical chromatography 
system utilizing Chiralpak (AD-H) column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. 
High-resolution mass spectra (HRMS) were acquired using an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in atmospheric pressure chemical ionization (APCI+), electrospray ionization 
(ESI+), or mixed (MultiMode: ESI-APCI) ionization mode. 
 
List of Abbreviations: ee - enantiomeric excess, dr - diastereomeric ratio, HPLC - high-performance liquid 
chromatography, UHPLC - Ultra high performance liquid chromatography SFC - supercritical fluid 
chromatography, TLC - thin-layer chromatography, THF - tetrahydrofuran, IPA - isopropanol, EtOAc - ethyl 
acetate, LAH - Lithium aluminium hydride, DCM - dichloromethane. 
 
                                                          
1
 Pangborn, A. M.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics, 1996, 15, 1518. 
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Experimental Procedures 
 
     
 
Salicylic alcohol (4). Salicylic acid (6.00 g, 43.4 mmol) was dissolved in diethyl ether (40 mL) and added to a 
solution of LAH (3.30 g, 87 mmol) in diethyl ether (300 mL) at 0 °C. The mixture was warmed to 23°C and 
stirred for 5 h. The mixture was quenched with 3.3 mL water and 3.3 mL 15% NaOH and 15 mL H2O. The 
mixture was stirred for 30 min. A white-gray precipitate formed. The precipitate was filtered off, diluted in 
water, acidified with 1M HCl and extracted with EtOAc (3x30 mL). The filtrate and the extracted organic 
fractions were dried with Na2SO4, filtered and concentrated under vacuum to give the crude product (7.3 g). The 
crude product was recrystallized from chloroform to give 2-(hydroxymethyl)phenol (5.01 g, 40.4 mmol, 93% 
yield). 
Rf = 0.6 (50% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ ppm 4.88 (s, 2 H), 6.87 (td, J=7.45, 0.98 Hz, 1 
H), 6.90 (dd, J=8.18, 0.85 Hz, 1 H), 7.03–7.07 (m, 1 H), 7.23 (td, J=7.69, 1.71 Hz, 1 H); 13C NMR (126 MHz, 
CDCl3) δ ppm 65.0, 116.8, 120.3, 125.0, 128.1, 129.8, 156.4; HRMS (MM: ESI-APCI+) m/z calc’d for C7H7O2 
[M-H+]=123.0452; found 123.0449. 
 
 
 
1,3,4,4a,5,8a-Hexahydro-1,4-ethenonaphthalene-3,5-bis(spirooxirane)2,6-dione (3). 
 2-(Hydroxymethyl)phenol 4 (1.00 g, 8.06 mmol) was dissolved in water (120 mL). A solution of sodium 
periodate (1.895 g, 8.86 mmol) in water (40 mL) was added. The mixture was stirred for 10 min and then put in 
a refrigerator (4 °C) for 24 h. The solid was filtered off and washed with cold water. The filtrate was extracted 
with EtOAc (3x10 mL). The organic phase was dried with Na2SO4 and concentrated. The solids were 
recrystallized from chloroform to give 1,3,4,4a,5,8a-hexahydro-1,4-ethenonaphthalene-3,5-bis(spirooxirane)2,6-
dione (876 mg, 3.59 mmol, 89% yield, dr: >20:1). 
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Rf = 0.25 (25% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ ppm 2.86 (dd, J=9.03, 2.44 Hz, 1 H), 2.88 (d, 
J=6.59 Hz, 1 H), 2.92–2.95 (m, 2 H), 2.97 (d, J=6.59 Hz, 1 H), 3.18 (d, J=6.10 Hz, 1 H), 3.52 (ddd, J=6.23, 
2.32, 1.46 Hz, 1 H), 3.56–3.60 (m, 1 H), 6.14–6.18 (m, 1 H), 6.23 (dd, J=10.25, 1.71 Hz, 1 H), 6.63–6.67 (m, 1 
H), 6.69 (dd, J=10.13, 4.27 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ ppm 38.5, 38.6, 41.5, 52.8, 53.4, 57.3, 
57.5, 58.5, 129.0, 131.1, 134.0, 146.6, 192.1, 203.1; HRMS (MM: ESI-APCI+) m/z calc’d for C14H11O4 [M-
H+]=243.0663; found 243.0662. 
 
 
 
(1S,4R)-5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-6,10(4H)-
dione (2). 1,3,4,4a,5,8a-Hexahydro-1,4-ethenonaphthalene-3,5-bis(spirooxirane)2,6-dione (375 mg, 1.54 mmol) 
was dissolved in water (10 mL) and stirred at 60 °C for 48h. The crude product was concentrated and purified by 
column chromatography (20% MeOH in EtOAc) to give (1S,4R)-5,9-dihydroxy-5,9-bis(hydroxymethyl)-
1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-6,10(4H)-dione (333 mg, 1.19 mmol, 77% yield). 
Rf= 0.15 (20% MeOH in EtOAc); 1H NMR (500 MHz, D2O) δ ppm 2.90–2.96 (m, 1 H), 3.31 (d, J=6.84 Hz, 1 
H), 3.38 (d, J=6.35 Hz, 1 H), 3.44 (d, J=12.21 Hz, 2 H), 3.52 (d, J=12.21 Hz, 1 H), 3.56 (d, J=11.96 Hz, 1 H), 
3.78 (d, J=11.96 Hz, 1 H), 5.94 (t, J=6.71 Hz, 1 H), 6.11 (dd, J=10.13, 1.34 Hz, 1 H), 6.34 (t, J=7.32 Hz, 1 H), 
6.70 (dd, J=10.01, 4.15 Hz, 1 H); 13C NMR (126 MHz, D2O) δ ppm 37.3, 40.0, 40.9, 52.1, 65.6, 70.7, 76. 5, 
79.1, 127.8, 128.9, 134.6, 148.7, 202.5, 212.4; HRMS (MM: ESI-APCI+) m/z calc’d for C14H16O6Cl1 [M+Cl-
]=315.0641; found 315.0647. 
 
 
 
(±)-Grandifloracin (1). To a solution of (1S,4R)-5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-
1,4-ethanonaphthalene-6,10(4H)-dione (2, 105 mg, 0.375 mmol) and cesium carbonate (366 mg, 1.12 mmol) in 
acetonitrile (2 mL), was added benzoyl chloride (0.087 mL, 0.75 mmol) and the mixture was stirred at 50 °C for 
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2 h. The mixture was concentrated and dissolved in 1:1 H2O:EtOAc (8 mL). The organic phase was collected 
and the water phase was extracted with EtOAc (2x5 mL). The combined organic phases were concentrated onto 
silica and purified by column chromatography (25% EtOAc in hexanes) to give (±)-grandifloracin (92 mg, 0.19 
mmol, 50% yield). 
Rf = 0.3 (33% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ ppm 3.34 (br. s., 1 H), 3.36–3.40 (m, 2 H), 
3.46 (ddt, J=8.45, 4.24, 1.83, 1.83 Hz, 1 H), 3.69 (dt, J=6.65, 1.80 Hz, 1 H), 4.24 (d, J=11.96 Hz, 1 H), 4.35 (s, 1 
H), 4.36–4.43 (m, 2 H), 4.47 (d, J=11.72 Hz, 1 H), 6.02 (ddd, J=7.93, 6.23, 1.47 Hz, 1 H), 6.20–6.24 (m, 1 H), 
6.44 (ddd, J=8.12, 6.78, 1.22 Hz, 1 H), 6.60 (dd, J=10.13, 4.27 Hz, 1 H), 7.41–7.45 (m, 2 H), 7.45–7.49 (m, 2 
H), 7.54–7.58 (m, 1 H), 7.58–7.62 (m, 1 H), 7.92–7.94 (m, 1 H), 7.94–7.95 (m, 1 H), 8.05–8.06 (m, 1 H), 8.06–
8.08 (m, 1 H); 13C NMR (126 MHz, CDCl3) δ ppm 37.4, 40.0, 41.1, 52.2, 68.2, 71.8, 74.4, 75.4, 128.1, 128.4 (s, 
2 C) 128.4 (s, 2 C) 128.5 (s, 2 C) 129.4, 129.7 (s, 2 C) 129.8 (s, 2 C) 133.3, 133.4, 135.2, 146.6, 165.8, 166.7, 
198.0, 208.0; HRMS (MM: ESI-APCI+) m/z calc’d for C28H24O8Cl1 [M+Cl-]=523.1165; found 523.1168. 
 
Chiral separation of Grandifloracin enantiomers: 
27 mg (±)-Grandifloracin was dissolved in 1 mL of acetone, diluted with 1 mL IPA and concentrated to 1 mL. 
The solution was injected onto a Chiralpak (AD-H) column (19 mm x 25 cm) chiral Prep-HPLC column to give 
(+)-grandifloracin (10 mg, 0.020 mmol, 38.6%, >99.5% ee, [α]D25+7.81 (c 0.45, CHCl3)) and (–)-grandifloracin 
(9 mg, 0.018 mmol, 34.8%, 96% ee, [α]D25–3.72 (c 0.45, CHCl3)). 
 
 
 
 
Condensed synthesis of (±)-Grandifloracin (1). 2-(hydroxymethyl)phenol (200 mg, 1.61 mmol) was dissolved 
in water (24 mL). A solution of sodium periodate (379 mg, 1.77 mmol) in water (8 mL) was added. The mixture 
was stirred for 10 min at 23 °C and then put in a refrigerator (4 °C) for 4h. A slightly yellow solid was filtered 
off and the filtrate was extracted with EtOAc (10 mL) and DCM (2x10 mL). The combined organic phases were 
concentrated until solid. The solid was dissolved in water (8 mL) and stirred at 60 °C for 48h. The crude product 
was concentrated to dryness under high-vacuum. The crude material was dissolved in acetonitrile (10 mL). 
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Cesium carbonate (2.1 g, 6.4 mmol) followed by benzoyl chloride (0.561 mL, 4.83 mmol) were added and the 
mixture was stirred at 50 °C for 2h. The mixture was concentrated, dissolved in DCM (5 mL) washed with H2O 
(2x5 mL). The organic phase is dried over Mg2SO4 and purified by column chromatography (33% EtOAc in 
hexanes) to afford (±)-grandifloracin (204 mg, 0.418 mmol, 52% yield). 
 
General procedure A for grandifloracin analogues. 
To a solution of (1S,4R)-5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (2, 1 equiv) and cesium carbonate (4 equiv) in acetonitrile (1 mL), was added acid chloride (3 
equiv) and the mixture was stirred at 50 °C for 2h. The mixture was concentrated and dissolved in 1:1 H2O: 
EtOAc (8 mL). The organic phase was collected and the water phase was extracted with EtOAc (2x5 mL). The 
combined organic phases were concentrated onto silica and purified by column chromatography. 
 
 
 
((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) bis(2-methylbenzoate) (7a). 
The product was synthesized according to general procedure A using 2-methylbenzoyl chloride (49.6 mg, 0.321 
mmol), yield: 26.7 mg, 0.052 mmol, 48%. 
Rf= 0.3 (2:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 2.54 (s, 3 H), 2.60 (s, 3 H), 3.33–3.42 (m, 3 H), 
3.45 (ddd, J=6.23, 4.15, 2.08 Hz, 1 H), 3.68 (d, J=6.59 Hz, 1 H), 4.19 (d, J=11.96 Hz, 1 H), 4.33 (br. s., 1 H), 
4.35 (d, J=11.23 Hz, 1 H), 4.39–4.44 (m, 1 H), 4.47 (d, J=11.96 Hz, 1 H), 6.00–6.05 (m, 1 H), 6.21 (dd, J=10.13, 
1.34 Hz, 1 H), 6.43 (t, J=7.20 Hz, 1 H), 6.59 (dd, J=10.13, 4.27 Hz, 1 H), 7.20–7.25 (m, 2 H), 7.25–7.29 (m, 2 
H), 7.37–7.46 (m, 2 H), 7.80 (d, J=7.81 Hz, 1 H), 7.95 (d, J=7.81 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ ppm 
21.7, 37.4, 40.0, 41.2, 52.3, 68.0, 71.7, 74.5, 75.5, 125.8, 125.8, 128.1, 128.5, 128.7, 128.8, 130.7, 130.8, 131.7, 
131.7, 132.3, 132.4, 135.2, 140.5, 140.6, 146.5, 166.7, 167.5, 198.2, 208.1,; IR (Neat Film NaCl) 3456, 2968, 
1723, 1602, 1457, 1383, 1292, 1251, 1142, 1077, 738 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C30H29O8 
[M+H+]=517.1857; found 517.1831. 
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((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) bis(3-methylbenzoate) (7b).  
The product was synthesized according to general procedure A using 3-methylbenzoyl chloride (49.6 mg, 0.321 
mmol), yield: 28.1 mg, 0.054 mmol, 51%. 
Rf= 0.3 (2:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 2.39 (s, 3 H), 2.42 (s, 3 H), 3.34–3.43 (m, 3 
H), 3.45 (ddd, J=6.29, 4.21, 1.95 Hz, 1 H), 3.68 (d, J=6.59 Hz, 1 H), 4.23 (d, J=11.96 Hz, 1 H), 4.34 (d, J=3.42 
Hz, 1 H), 4.36 (s, 1 H), 4.39–4.44 (m, 1 H), 4.46 (d, J=11.96 Hz, 1 H), 5.99–6.04 (m, 1 H), 6.21 (dd, J=10.13, 
1.34 Hz, 1 H), 6.44 (t, J=7.32 Hz, 1 H), 6.59 (dd, J=10.13, 4.27 Hz, 1 H), 7.28–7.33 (m, 1 H), 7.34–7.38 (m, 2 
H), 7.38–7.42 (m, 1 H), 7.72 (d, J=7.81 Hz, 1 H), 7.75 (s, 1 H), 7.84–7.88 (m, 2 H); 13C NMR (126 MHz, 
CDCl3) δ ppm 21.2, 37.5, 40.0, 41.2, 52.3, 68.2, 71.8, 74.5, 75.4, 126.8, 127.0, 128.1, 128.3, 128.4, 129.3, 130.2, 
130.4, 134.1, 134.2, 135.2, 138.3, 138.3, 146.5, 166.0, 166.9, 198.1, 208.0; IR (Neat Film NaCl) 3454, 2922, 
1722, 1589, 1450, 1382, 1276, 1198, 1102, 1082, 743 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C30H29O8 
[M+H+]=517.1857; found 517.1836. 
 
 
 
((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) bis(4-methylbenzoate) (7c). 
The product was synthesized according to general procedure A using 3-methylbenzoyl chloride (49.6 mg, 0.321 
mmol), yield: 30.6 mg, 0.059 mmol, 55%. 
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Rf= 0.3 (2:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 2.40 (s, 3 H), 2.42 (s, 3 H), 3.34–3.40 (m, 2 
H), 3.40–3.49 (m, 2 H), 3.68 (d, J=6.59 Hz, 1 H), 4.22 (d, J=11.96 Hz, 1 H), 4.33–4.41 (m, 3 H), 4.45 (d, 
J=11.96 Hz, 1 H), 6.01 (t, J=6.59 Hz, 1 H), 6.20 (dd, J=10.13, 1.34 Hz, 1 H), 6.43 (t, J=7.32 Hz, 1 H), 6.58 (dd, 
J=10.13, 4.27 Hz, 1 H), 7.21 (d, J=8.06 Hz, 2 H), 7.25 (d, J=8.06 Hz, 2 H), 7.82 (d, J=8.06 Hz, 2 H), 7.94 (d, 
J=8.30 Hz, 2 H); 13C NMR (126 MHz, CDCl3) δ ppm 21.6, 21.6, 37.5, 40.0, 41.2, 52.3, 68.1, 71.7, 74.5, 75.5, 
126.7, 128.1, 128.4, 129.2, 129.2, 129.7, 129.9, 135.2, 144.0, 144.2, 146.6, 165.9, 166.8, 198.1, 208.0; IR (Neat 
Film NaCl) 3452, 2923, 1721, 1611, 1449, 1408, 1380, 1271, 1179, 1098, 1020, 751 cm-1;  HRMS (MM: ESI-
APCI+) m/z calc’d for C30H29O8 [M+H+]=517.1857; found 517.1838. 
 
 
 
((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) bis(4-methoxybenzoate) (7d). 
The product was synthesized according to general procedure A using 4-methoxybenzoyl chloride (54.8 mg, 
0.321 mmol), yield: 40.7 mg, 0.074 mmol, 69%. 
Rf= 0.2 (2:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 3.34–3.39 (m, 2 H), 3.44 (ddt, J=8.39, 4.18, 
1.89, 1.89 Hz, 2 H), 3.67 (dt, J=6.59, 1.71 Hz, 1 H), 3.85 (s, 3 H), 3.86 (s, 3 H), 4.20 (d, J=11.96 Hz, 1 H), 4.31–
4.39 (m, 3 H), 4.43 (d, J=11.96 Hz, 1 H), 6.00 (ddd, J=7.93, 6.23, 1.46 Hz, 1 H), 6.20 (dd, J=10.13, 1.59 Hz, 1 
H), 6.43 (ddd, J=8.06, 6.84, 1.22 Hz, 1 H), 6.58 (dd, J=10.13, 4.27 Hz, 1 H), 6.88–6.91 (m, 2 H), 6.91–6.94 (m, 
2 H), 7.86–7.90 (m, 2 H), 7.99–8.02 (m, 2 H); 13C NMR (126 MHz, CDCl3) δ ppm 37.5, 40.0, 41.2, 52.3, 55.4, 
55.5, 68.0, 71.6, 74.5, 75.5, 110.0, 113.8, 113.8, 121.8, 128.1, 128.4, 131.8, 132.0, 135.3, 146.6, 163.7, 163.8, 
165.5, 166.4, 198.2, 208.0; IR (Neat Film NaCl) 3450, 2937, 1712, 1605, 1512, 1459, 1420, 1359, 1317, 1258, 
1099, 1027, 847, 767 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C30H29O10 [M+H+]=549.1755; found 
549.1735. 
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((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) bis(4-cyanobenzoate) (7e). 
The product was synthesized according to general procedure A using 4-cyanobenzoyl chloride (53.2 mg, 0.321 
mmol), yield: 14.2 mg, 0.026 mmol, 25%. 
Rf= 0.25 (2:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 3.20 (br. s., 1 H), 3.35 (d, J=8.30 Hz, 1 H), 
3.42 (d, J=5.86 Hz, 1 H), 3.44–3.49 (m, 1 H), 3.67 (d, J=6.59 Hz, 1 H), 4.26 (d, J=11.96 Hz, 1 H), 4.34 (br. s., 1 
H), 4.42 (s, 2 H), 4.50 (d, J=11.96 Hz, 1 H), 6.06 (t, J=6.84 Hz, 1 H), 6.23 (d, J=10.01 Hz, 1 H), 6.44 (t, J=7.32 
Hz, 1 H), 6.63 (dd, J=10.25, 4.15 Hz, 1 H), 7.73 (m, J=8.30 Hz, 2 H), 7.77 (d, J=8.30 Hz, 2 H), 8.03 (d, J=8.30 
Hz, 2 H), 8.16 (m, J=8.30 Hz, 2 H); 13C NMR (126 MHz, CDCl3) δ ppm 37.1, 39.9, 40.8, 52.0, 68.8, 72.2, 74.2, 
75.3, 116.8, 116.9, 117.8, 127.9, 128.7, 130.2, 130.3, 132.3, 132.3, 133.0, 133.1, 134.8, 146.8, 164.1, 165.0, 
197.7, 208.0; IR (Neat Film NaCl) 3450, 2923, 2853, 2231, 1727, 1450, 1377, 1271, 1178, 1099, 1019, 861, 
804, 764 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C30H23N2O8 [M+H+]= 501.2483; found 501.2464.  
 
 
((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) dicyclohexanecarboxylate (7f).  The product was synthesized according to general 
procedure A using cyclohexane carbonyl chloride (34.5 mg, 0.235 mmol), yield: 31.3 mg, 0.063 mmol, 58%. 
Rf= 0.3 (4:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 1.21–1.29 (m, 5 H), 1.30–1.40 (m, 3 H), 1.40–
1.49 (m, 2 H), 1.60–1.68 (m, 2 H), 1.70–1.86 (m, 7 H), 1.89–1.97 (m, 2 H), 2.25 (tt, J=11.20, 3.57 Hz, 1 H), 2.37 
(tt, J=11.32, 3.57 Hz, 1 H), 3.22 (dd, J=8.30, 1.71 Hz, 1 H), 3.29–3.34 (m, 1 H), 3.37 (ddd, J=6.23, 4.15, 2.08 
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Hz, 1 H), 3.51 (d, J=6.59 Hz, 1 H), 3.92 (d, J=11.96 Hz, 1 H), 4.09 (d, J=11.23 Hz, 1 H), 4.17–4.22 (m, 2 H), 
4.25 (d, J=11.96 Hz, 1 H), 5.93–5.99 (m, 1 H), 6.15 (dd, J=10.13, 1.59 Hz, 1 H), 6.31–6.37 (m, 1 H), 6.54 (dd, 
J=10.13, 4.27 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ ppm 25.3, 25.3, 25.4 (s, 2 C) 25.7 (s, 2 C) 28.8, 28.9, 
29.0 (s, 2 C) 37.3, 40.0, 41.1, 42.9, 43.1, 52.3, 67.5, 70.9, 74.4, 75.5, 128.1, 128.4, 135.1, 146.3, 175.3, 176.2, 
198.0, 207.9; IR (Neat Film NaCl) 3447, 2932, 2855, 2361, 1734, 1456, 1387, 1313, 1246, 1166, 1131, 1038, 
754 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C28H37O8 [M+H+]= 501.2483; found 501.2464. 
 
 
 
 
((1S,4R,4aR,8aS)-5,9-dihydroxy-6,10-dioxo-1,4,4a,5,6,8a-hexahydro-1,4-ethanonaphthalene-5,9-
diyl)bis(methylene) dicyclopropanecarboxylate (7g). 
The product was synthesized according to general procedure A using cyclopropanecarbonyl chloride (33.6 mg, 
0.321 mmol), yield: 24.5 mg, 0.059 mmol, 55.0%. 
Rf= 0.25 (4:1Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm 0.84–0.88 (m, 2 H), 0.92–0.98 (m, 4 H), 
1.01–1.06 (m, 2 H), 1.56 (tt, J=8.06, 4.64 Hz, 1 H), 1.68 (tt, J=8.06, 4.64 Hz, 1 H), 3.21 (br. s., 1 H), 3.24 (dd, 
J=8.42, 2.08 Hz, 1 H), 3.30–3.34 (m, 1 H), 3.35–3.40 (m, 1 H), 3.55 (dt, J=6.59, 1.71 Hz, 1 H), 3.94 (d, J=11.96 
Hz, 1 H), 4.12 (d, J=11.23 Hz, 1 H), 4.19 (d, J=11.23 Hz, 1 H), 4.22 (s, 1 H), 4.26 (d, J=11.96 Hz, 1 H), 5.96 
(ddd, J=7.93, 6.23, 1.46 Hz, 1 H), 6.17 (dd, J=10.01, 1.71 Hz, 1 H), 6.36 (ddd, J=8.00, 6.65, 1.22 Hz, 1 H), 6.55 
(dd, J=10.13, 4.27 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ ppm 8.7, 8.7, 8.9, 9.0, 12.7, 12.8, 37.3, 40.0, 41.1, 
52.3, 67.8, 71.3, 74.4, 75.4, 128.1, 128.4, 135.2, 146.4, 174.2, 175.2, 198.0, 207.8; IR (Neat Film NaCl) 3447, 
3014, 2917, 1730, 1457, 1399, 1267, 1169, 1098, 1077, 1034, 752 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d 
for C22H25O8 [M+H+]= 417.1544; found 417.1540. 
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